Study shows longer-term benefit of one-month dual antiplatelet therapy after intervention
Physical activity and sedentary behavior both increased during COVID lockdown, new research reveals
29 August 2022Exploring the brief use of rapamycin treatment in early adulthood to extend lifespan
29 August 2022Study shows longer-term benefit of one-month dual antiplatelet therapy after intervention
A prespecified analysis of the MASTER DAPT trial has confirmed that the absence of ischemic risk and reduction in bleeding with abbreviated dual antiplatelet therapy (DAPT) in patients at high bleeding risk undergoing intervention persists beyond one year of follow up. The late breaking research is presented in a Hot Line session on 29 August at ESC Congress 2022.
